Skip to main content
. 2019 Nov 15;19:109–123. doi: 10.1016/j.omtn.2019.11.003

Figure 1.

Figure 1

The Clinical Significance of lncRNA MAGI2-AS3 Expression Was Analyzed in TCGA-STAD Cohort

(A) Difference in expression levels of MAGI2-AS3 between GSE79973 and GSE54129 stomach cancer cohorts. (B) Difference in expression levels of MAGI2-AS3 between intestinal gastric cancer tissues and diffuse gastric cancer tissues. (C) Difference in expression levels of MAGI2-AS3 in gastric cancer tissues with different degrees of differentiation. (D–G) MAGI2-AS3 expression level in different T stages (D), pathologic stages (E), N stages (F), and M stages (G) of gastric cancer. (H and I) Kaplan-Meier analysis of overall survival time (H) and disease-free time (I) of patients with gastric cancer according to the expression of lncRNA MAGI2-AS3. ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05.